Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -521.61% is 67% above its 5-year average of -1573.71%, near the high end of its 5-year range (-7881.09%–225.36%).
68.27% above its 12-month average of -1644.10%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1487.43%.
EBITDA MARGIN
-521.61%
EBITDA MARGIN AVG TTM
-1644.10%
EBITDA MARGIN AVG 3Y
-1361.89%
EBITDA MARGIN AVG 5Y
-1573.71%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+68.27%
CURRENT VS 3Y AVG
+61.70%
CURRENT VS 5Y AVG
+66.85%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Lipocine Inc.
Market Cap
$17.07M
EBITDA Margin
-521.61%
TTM Avg
-1644.10%
3Y Avg
-1361.89%
5Y Avg
-1573.71%
Market Cap
$17.14M
EBITDA Margin
-65.27%
TTM Avg
-65.27%
3Y Avg
-407.18%
5Y Avg
-920.02%
Market Cap
$17.27M
EBITDA Margin
-30564.79%
TTM Avg
-16005.09%
3Y Avg
-14551.39%
5Y Avg
-13807.79%
Market Cap
$16.84M
EBITDA Margin
-168.69%
TTM Avg
-262.41%
3Y Avg
-983.34%
5Y Avg
-3401.51%
Market Cap
$16.70M
EBITDA Margin
-82.81%
TTM Avg
-187.23%
3Y Avg
-342.47%
5Y Avg
-369.32%
Market Cap
$17.50M
EBITDA Margin
-23.24%
TTM Avg
-24.75%
3Y Avg
-25.93%
5Y Avg
-17.56%
Market Cap
$16.50M
EBITDA Margin
-1287.62%
TTM Avg
-2964.71%
3Y Avg
-1700.58%
5Y Avg
-1592.26%
Market Cap
$16.40M
EBITDA Margin
-579.88%
TTM Avg
-374.35%
3Y Avg
-344.55%
5Y Avg
-411.92%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lipocine Inc. (LPCN) | $17.07M | -521.61% | -1644.10% | -1361.89% | -1573.71% |
| Palatin Technologies, Inc. (PTN)vs › | $17.14M | -65.27% | -65.27% | -407.18% | -920.02% |
| PAVmed Inc. (PAVM)vs › | $17.27M | -30564.79% | -16005.09% | -14551.39% | -13807.79% |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | -168.69% | -262.41% | -983.34% | -3401.51% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.70M | -82.81% | -187.23% | -342.47% | -369.32% |
| Cosmos Health Inc. (COSM)vs › | $17.50M | -23.24% | -24.75% | -25.93% | -17.56% |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.50M | -1287.62% | -2964.71% | -1700.58% | -1592.26% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $17.71M | N/A | N/A | N/A | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.40M | -579.88% | -374.35% | -344.55% | -411.92% |
| BioCardia, Inc. (BCDA)vs › | $15.85M | -13679.31% | -8051.39% | -4553.85% | -5076.49% |
Gross Margin
-334.3%
EBITDA Margin
-521.6%
Operating Margin
-524.7%
Net Margin
-755.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1487.43% |
| 2026-03-31 | -3211.68% |
| 2025-12-31 | -218.51% |
| 2025-09-30 | -2919.45% |
| 2025-06-30 | -383.44% |
| 2025-03-31 | -2210.23% |
| 2024-12-31 | 44.71% |
| 2024-06-30 | -3666.67% |
| 2024-03-31 | 42.42% |
| 2023-12-31 | -1195.88% |
| 2023-09-30 | 225.36% |
| 2023-03-31 | -7881.09% |
| 2022-06-30 | -704.99% |
| 2021-12-31 | 79.48% |
| 2021-09-30 | -6425.56% |
| 2019-09-30 | -1801.22% |
| 2018-03-31 | -614.84% |
